ALGS Aligos Therapeutics
Price Chart
Executive Summary
Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for pevifoscorvir sodium in chronic HBV infection. The data suggest 40% of HBeAg+ patients with HBsAg ≥3,000 IU/mL achieved reductions qualifying them for potential functional cure regimens, and preclinical data showed additive-to-synergistic effects when combined with the ASO ALG-170675. This is a routine scientific update with no regulatory decision or financial results, and historical T+20 performance on this ticker has been poor (29% win rate, -3.63% average return).
Actionable Insight
This press release is a scientific data update, not a regulatory or financial catalyst. The 40% HBsAg reduction signal in a small Phase 1 subgroup is encouraging but early — watch for Phase 2 initiation and enrollment updates for pevifoscorvir sodium. Given the tiny market cap ($36M) and poor historical T+20 returns on ALGS filings, traders should wait for a more concrete catalyst (Phase 2 start, data from the B-SUPREME study, or partnership deal) before establishing a position.
Key Facts
- Phase 1 long-term follow-up data on 10 HBeAg+ subjects: 4 of 9 (44%) maintained HBV DNA below LLOQ during ≥24 weeks of NA-only follow-up post 96-week pevifoscorvir monotherapy.
- 40% of evaluable HBeAg+ participants with baseline HBsAg ≥3,000 IU/mL achieved HBsAg <3,000 IU/mL at week 48, suggesting potential eligibility for functional cure therapy with an ASO agent.
- Preclinical in vitro data showed additive-to-synergistic antiviral effects when ALG-001075 (active parent of pevifoscorvir) was combined with the ASO ALG-170675.
- Pevifoscorvir sodium is being developed as a potential first-in-class CAM-E with a proposed secondary mechanism reducing the cccDNA reservoir.
- Data presented at EASL Congress 2026, May 27-30, in Barcelona, Spain. No new financial data, regulatory filing, or enrollment milestones were announced.
Financial Impact
No revenue, financial results, or guidance were disclosed. Impact on valuation depends on subsequent clinical and regulatory milestones.
Risk Factors
- Phase 1 data are from 10 subjects — very small sample size limits statistical reliability.
- No regulatory or Phase 2 enrollment catalysts in this update; 40% HBsAg reduction threshold is a biomarker, not a functional cure endpoint.
- ALGS has a 29% win rate T+20 on prior reports and average T+20 return of -3.63% — the stock has historically sold off on company announcements.
- Pevifoscorvir sodium is still early-stage; competition from other CAM-E and ASO programs in HBV could limit differentiation.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
19d ago
|
Press Release
| $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $5.28 (−5.71%) |
|
Apr 16, 2026
8w ago
|
Press Release
| $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $5.28 (−31.07%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $5.28 (−28.84%) |
|
Mar 5, 2026
14w ago
|
8-K
| $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $5.28 (−20.72%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $5.28 (−20.72%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $5.28 (−24.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access